Coloplast A/S - Coloplast presents new 5-year strategy, Impact4

The new 5-year strategy,  Impact4, will be presented today at the company’s Capital Markets Day 2025 TheImpact4strategy puts customers at the centre of everything we do and sets an ambitious goal for the company – to help 4 million people in the long-term. WithImpact4, we focus on four strategic priorities which are essential to our success and value creation:Grow through innovative customer offerings, by setting the standard of care and driving strong customer centricity...

Humlebaek, 02/09/2025 (informazione.news - comunicati stampa - salute e benessere)

The strategy puts customers at the centre of everything we do and sets an ambitious goal for the company – to help 4 million people in the long-term. With , we focus on four strategic priorities which are essential to our success and value creation:

Ahead of the new strategic period, we are organising our businesses into two distinct business units: Chronic Care and Acute Care, as announced on 19 August 2025. This allows the company to respect the differences in market dynamics, customer needs, patient pathways and business models. As a consequence of the new business unit structure, a new Executive Leadership Team was also announced on 19 August 2025, to successfully lead the execution of the strategy.

Together with the rest of the Board of Directors and Executive Leadership Team at Coloplast, I am excited to present to you our new 5-year strategy, . The strategic priorities we have laid out in set a clear direction – one where our customers are at the centre of everything we do. We are reinvigorating our focus on delivering the best customer experience for our users, patients and clinicians across our offering of products, support and services, with the ambition to lead the market and win. I firmly believe our new strategy will create value for all our stakeholders – customers, shareholders, employees and partners.’’ says Lars Rasmussen, interim CEO of Coloplast.

The Capital Markets Day will start at 10.30h CEST today with a plenary session, covering the introduction of the new Group strategy, Group financial update and the strategy for the Chronic Care business unit.

In the afternoon, there will be a series of breakout sessions with Executive Leadership and other key representatives from Coloplast, covering a strategic update on US Chronic Care and Emerging Markets Chronic Care, Wound and Tissue Repair, Interventional Urology, Global Operations and People and Culture.

The event will be held in person at the Clarion Hotel in Copenhagen, Denmark. To participate in the plenary session of the Capital Markets Day 2025 virtually, please follow the link here: Coloplast Capital Markets Day 2025. All material from the Capital Markets Day will be made available during the day on Coloplast’s website: Investors.

1. The new financial ambition includes the following key assumptions:

2. In constant currencies; before special items

3. Introduction of reimbursement for transanal irrigation as of 1 October 2025 by Medicare

Contacts:
Investors:
Aleksandra Dimovska
Vice President, Investor Relations
Tel. +45 4911 1800 / +45 4911 2458
Email: dkadim@coloplast.com

Kristine Husted Munk
Senior Director, Investor Relations 
Tel. +45 4911 1800 / +45 4911 3266
Email: dkkhu@coloplast.com

Simone Dyrby Helvind
Senior Manager, Investor Relations
Tel. +45 4911 1800 / +45 4911 2981
Email: dksdk@coloplast.com

Media:
Peter Mønster
Senior Media Relations Manager
Tel. +45 4911 2623
Email: dkpete@coloplast.com

Address
Coloplast A/S
Holtedam 1
DK-3050 Humlebaek
Denmark
Company reg. (CVR) no. 69749917

Website
www.coloplast.com

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail.

 

Attachment